Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Inclusion Criteria: 1. Men aged 18 to 90 years with a histologic diagnosis of prostate cancer; 2. c. Biochemical recurrence following local therapy, either surgery or radiation. Rising PSA defined as: * After definitive surgery, e.g. * After radical prostatectomy, two PSA measurements of ≥ 1.0 ng/mL at least one week apart; * After cryosurgery, two PSA measurements of ≥ 2.0 ng/mL at least one week apart; * Other definitive surgical procedures may be permissible upon the approval of the medical monitor OR * After radiation therapy (e.g., external beam radiation, brachytherapy, or salvage/adjuvant radiation therapy after surgery), two post radiation PSA measurements level of nadir plus 2.0 ng/mL at least one week apart.; 3. Serum testosterone level: i) Subjects with no history of androgen deprivation therapy: * A single measurement greater than 150 ng/dL or 5.2 nmol/L within 3 months of enrollment ii) Subjects with a history of androgen deprivation therapy (either in adjuvant or biochemical relapse setting): * The two most recent measurements of serum testosterone prior to enrollment must fulfill the following criteria: * Both measurements are greater than 150 ng/dL or 5.2 nmol/L; * The two measurements are spaced at least 14 days apart; * Both must be measured within 3 months of enrollment; 4. Normal electro cardio gram (ECG) or ECG with no clinically significant findings; 5. Adequate bone marrow, hepatic, and renal function tests within 30 days prior to enrollment: * CBC (except platelets and hemoglobin), serum chemistry, liver panel, and CPK values ≤ Grade 1 abnormality as defined in CTCAE v 4.03 dated June 14, 2010 * Platelets ≥ 75,000 /mL; * Hemoglobin ≥ 9.0 g/dL; 6. No desire or plans to father new children during the study and/or have a prior vasectomy Exclusion Criteria: 1. PSA doubling time (PSA-DT) of ≤ 3 months, using 2 PSA values at least 4 weeks apart, calculated according to the Memorial Sloan-Kettering Cancer Center nomogram (https://www.mskcc.org/nomograms/prostate/psa-doubling-time); 2. Clinical or radiologic evidence of distant metastatic disease other than small volume (\<1.5 cm) nodes, this should be tested within 12 months from enrollment; 3. Receipt of investigational therapy in a clinical trial setting within 30 days of enrollment; 4. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome; 5. Prior major surgery or radiation therapy within 4 weeks of enrollment; 6. Any prior chemotherapy, except short-course neo-adjuvant or adjuvant chemotherapy that had been stopped for at least 6 weeks prior to Study enrollment; 7. Active AIDS / HIV infection, clinically uncontrolled immune deficiency disorders; 8. Clinically uncontrolled autoimmune disorders, transplant recipients who depend on immunosuppressive therapy, other immunosuppressive conditions including any concurrent condition requiring immunosuppressive/immunomodulating agents; 9. Recipient of any blood product and immunotherapy (such as anti-PD1, anti-PDL-1 and anti-CTLA4) within 3 months of enrollment;